M&T Bank Corp Has $1.45 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

M&T Bank Corp trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 15.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,427 shares of the medical equipment provider's stock after selling 4,153 shares during the quarter. M&T Bank Corp's holdings in Hologic were worth $1,448,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. Beverly Hills Private Wealth LLC boosted its stake in Hologic by 3.6% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after purchasing an additional 180 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Hologic by 4.8% during the 1st quarter. Crossmark Global Holdings Inc. now owns 34,137 shares of the medical equipment provider's stock worth $2,109,000 after acquiring an additional 1,549 shares in the last quarter. Penserra Capital Management LLC boosted its stake in shares of Hologic by 2,069.5% during the 1st quarter. Penserra Capital Management LLC now owns 13,212 shares of the medical equipment provider's stock worth $815,000 after acquiring an additional 12,603 shares in the last quarter. IFM Investors Pty Ltd boosted its stake in shares of Hologic by 12.0% during the 1st quarter. IFM Investors Pty Ltd now owns 56,081 shares of the medical equipment provider's stock worth $3,464,000 after acquiring an additional 5,996 shares in the last quarter. Finally, OneDigital Investment Advisors LLC boosted its stake in shares of Hologic by 7.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 7,247 shares of the medical equipment provider's stock worth $448,000 after acquiring an additional 528 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Up 0.9%

Shares of HOLX stock traded up $0.58 on Wednesday, hitting $63.84. The stock had a trading volume of 571,681 shares, compared to its average volume of 2,381,879. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The firm has a market cap of $14.23 billion, a P/E ratio of 26.94, a PEG ratio of 2.37 and a beta of 0.55. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The company has a fifty day moving average price of $61.99 and a two-hundred day moving average price of $63.35.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same quarter in the previous year, the business earned $1.03 EPS. The firm's revenue was down 1.2% on a year-over-year basis. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on HOLX shares. Mizuho increased their price objective on Hologic from $65.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Evercore ISI raised their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Finally, Stephens decreased their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic presently has an average rating of "Hold" and a consensus price target of $77.33.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director directly owned 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.88% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.